Vaso's Unit Amends Sales Representation Deal With GE Healthcare To Extend Term Agreement Through Dec. 31, 2030

Vaso Corporation (OTCQX: VASO) announced today that its wholly owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, has signed an amendment to the sales representation agreement with GE HealthCare (NASDAQ:GEHC) to extend the term of the agreement through December 31, 2030. This is the fifth time the parties have agreed to extend the term of the agreement and establishes a significant milestone in this longstanding collaboration, which began in May 2010. By virtue of the latest extension, the relationship will ultimately span over 20 years, reinforcing the shared commitment to advancing diagnostic imaging and ultrasound solutions across the United States.

Under the terms of this latest amendment, VasoHealthcare will continue to represent GE HealthCare's portfolio of diagnostic imaging and ultrasound products and services, including CT, MR, molecular imaging, X-ray, mammography, and interventional guided solutions systems, as well as associated service and financial offerings. The amendment builds upon the success of the long-term relationship, ensuring continuity in sales representation and alignment with GE HealthCare's commercial strategy. The collaboration has consistently delivered strong results, leveraging VasoHealthcare's expertise and GE HealthCare's technologies to help improve patient outcomes and support healthcare providers in meeting evolving clinical demands. This extension underscores both organizations' dedication to delivering cutting-edge technology and exceptional customer support to healthcare providers nationwide.